Dexcom (DXCM): STATE STREET CORP discloses a stake of more than 5% (Schedule 13G)
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
State Street Corp. disclosed a stake exceeding 5% in Dexcom (DXCM) via a Schedule 13G filing with the SEC, accession number 0000093751-26-000645. The filing signals that the institutional investor has crossed the 5% beneficial ownership threshold that triggers disclosure requirements for major shareholders. Dexcom, a continuous glucose monitoring device maker, now counts State Street among its largest institutional holders. The exact share count and percentage were not specified in the filing summary. Investors will watch for further 13G amendments or 13D filings that could indicate whether State Street's position is passive or activist in nature.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
Dexcom (DXCM), State Street Corp
A linked name opens that asset's sentiment page.